What’s Next For ICER: An Interview With New President Sarah Emond

The Institute for Clinical and Economic Review’s (ICER’s) new president and CEO Sarah Emond took over the role from the organization’s longtime leader and founder Steve Pearson on Jan. 1, and in an interview at the J.P. Morgan Healthcare Conference in San Francisco, she discussed some of the pressing drug pricing issues on ICER’s radar for the year ahead.

Emond has had a lengthy career at ICER, having worked for the organization for 14 years — most recently as vice president and chief operating officer, helping to lead strategic operations. She said the leadership change was part of a long and planned transition and Pearson continues to work as an advisor.

© 2024 MMIT
Jessica Merrill

Jessica Merrill

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Related Posts

pills-and-money
January 11

Obesity Meds, Gene Therapies, NASH Drug Make Payers’ Cost Concern List

READ MORE
pills
November 9

ICER Sets Sights on Expanding ‘Fair Access’ Formulary Analysis

READ MORE
medications-and-bills
December 14

Humira, Entresto, Other Drugs Make ICER’s Unsupported-Price-Hike Naughty List

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today